On October 2, 2026 Jecho Laboratories, Inc. reported it will present emerging clinical data from an open-label, multi-center Phase 1 study of JLM019, a CD80/PD-1 dual target Fc fusion protein, under evaluation for safety, tolerability, and preliminary efficacy in patients with advanced malignancies. Jecho will also present preclinical data from JLM070, a PD-L1-directed 4-1BB ligand fusion protein, as a next-generation immuno-oncology agent designed to overcome systemic toxicities from first generation 4-1BB antibodies and with a wider therapeutic window than second-generation conditionally activated bispecific antibodies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The SITC (Free SITC Whitepaper) meeting will be held November 4-8, 2026, in Phoenix, AZ.

Details of the presentations are below:

A Phase I Study to Evaluate the Safety and Tolerability of JLM019 Injection in patients with advanced malignancies

Abstract Presentation Number: 564
Session Time: Saturday, November 7
Location: Phoenix Convention Center, North Building, Lower Level, Exhibition Halls 4-6
SITC link: TBD
A novel PD-L1-directed 4-1BB ligand fusion protein, JLM070, demonstrates potent antitumor activity and a favorable safety profile in preclinical models

Abstract Presentation Number: 967
Session Time: Friday, November 6
Location: Phoenix Convention Center, North Building, Lower Level, Exhibition Halls 4-6
SITC link: TBD

(Press release, Jecho Laboratories, OCT 3, 2026, View Source [SID1234671259])